The current epidemic in the Democratic Republic of the Congo is caused by Bundibugyo ebolavirus and has become the largest Ebola outbreak in the country’s history and the second-largest Ebola epidemic recorded. Despite major investments after the 2014–2016 West Africa epidemic that improved outbreak science, most countermeasures and systems were optimized for Zaire ebolavirus (EBOV). This species-focused approach left global preparedness vulnerable when a different Ebola virus species emerged.
These vulnerabilities span diagnostics, vaccines, therapeutics, clinical trial activation, and manufacturing pathways. The outbreak demonstrates that concentrating effort and resources on the virus responsible for the last crisis does not guarantee readiness for other pathogenic members of the same virus family.
Early in the Bundibugyo outbreak, several molecular assays developed and optimized for EBOV performed poorly against Bundibugyo virus, causing diagnostic delays until updated assays were designed and deployed. This was not solely a technical failure: it reflected an underlying assumption that pathogen-specific diagnostics would generalize across genetically distinct Ebola virus species.
Surveillance systems built around a single pathogen are prone to blind spots if viral diversity is overlooked. The experience in this outbreak underscores the need for diagnostic strategies that account for genetic variation across filoviruses, rather than relying exclusively on assays keyed to a single species.
The licensed rVSV-ZEBOV vaccine (Ervebo) transformed the response to EBOV outbreaks and remains a landmark scientific achievement. However, Ervebo was designed to target the glycoprotein of EBOV, and its effectiveness against Bundibugyo virus was uncertain.
Recognizing that uncertainty, the World Health Organization recommended in May that Ervebo not be used routinely in the Bundibugyo outbreak outside of research settings due to insufficient evidence of cross-species effectiveness. Since then, preliminary laboratory studies, immunologic data, and ancillary analyses from the outbreak suggest Ervebo may elicit immune responses that provide at least partial cross-protection. These findings remain early and are not yet sufficient to establish meaningful clinical effectiveness.
The critical takeaway is not whether Ervebo ultimately protects against Bundibugyo virus, but that these evidence gaps should have been addressed before a major outbreak. Preparedness requires proactive generation of vaccine efficacy and cross-protection data against diverse filoviruses, rather than resolving these questions amid an emergency.
Therapeutic research during the outbreak reflects both progress and the limits of species-specific preparedness. Investigators have moved quickly to evaluate treatments specifically for Bundibugyo virus disease. The WHO-led PARTNERS trial is assessing remdesivir and the broadly neutralizing monoclonal antibody MBP134, alone and in combination. The EBO-PEP study is testing oral obeldesivir as post-exposure prophylaxis among high-risk contacts.
Within EBO-PEP, remdesivir is being provided on a compassionate-use basis for pregnant and lactating women and children under 12 who are not eligible for obeldesivir. These measures highlight the advantage of international clinical trial networks that can be activated rapidly during emergencies — a capability built after the West Africa epidemic — while also illustrating that many key scientific questions are being answered while transmission continues rather than beforehand.
The outbreak makes clear that preparedness should anticipate viral diversity and biological uncertainty. Practical priorities include:
These investments may appear costlier upfront but are argued to be far less expensive than repeatedly rebuilding a response when a related but distinct virus emerges.
The authors draw parallels to other preparedness misalignments: pandemic planning that centered on influenza before SARS-CoV-2 and the neglect of mpox before it became a global emergency. The Bundibugyo outbreak delivers a similar lesson for Ebola: preparedness cannot mean optimizing investments for yesterday’s epidemic.
Policy and funding decisions should prioritize adaptable platforms and cross-species evidence generation. The rapid initiation of Bundibugyo-specific vaccine Phase 1 trials by the University of Oxford and the Serum Institute of India, and a Moderna mRNA Phase 1 trial, demonstrates that scientific response can be swift when political and financial will align. But the authors emphasize that many of the fundamental questions about diagnostics, vaccines, and therapeutics ideally should have been answered in advance.
Ultimately, the recommendation is to invest in systems and products that remain effective across the biological diversity of filoviruses so that when the next outbreak surprises us, our preparedness systems do not.